Paper33944896
FT-4202, an oral PKR activator, has potent antisickling effects and improves RBC survival and Hb levels in SCA mice.
Shrestha A and 8 others. Blood Adv, 2021. Cited by 27 papers, by iCite.
Cite this record
ConductScience Library. FT-4202, an oral PKR activator, has potent antisickling effects and improves RBC survival and Hb levels in SCA mice. Papers, record 33944896. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33944896
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- FT-4202, an oral PKR activator, has potent antisickling effects and improves RBC survival and Hb levels in SCA mice.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anemia, Sickle Cell | Major topic |
| Hemoglobin, Sickle | Major topic |
| Animals | |
| Antisickling Agents | |
| Erythrocytes, Abnormal | |
| Humans | |
| Mice | |
| Pyruvate Kinase |
Source PubMed
References31
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 30097462 | Elevated ecto-5'-nucleotidase: a missing pathogenic factor and new therapeutic target for sickle cell disease. | Blood Adv | 2018 | https://conductscience.org/library/papers/30097462 | PubMed |
| 2 | 6499204 | Increased calcium uptake in the red cells of unsplenectomized patients with hereditary spherocytosis: significant contribution of reticulocytosis. | Clin Chim Acta | 1984 | https://conductscience.org/library/papers/6499204 | PubMed |
| 3 | 24589263 | Therapeutic strategies to alter the oxygen affinity of sickle hemoglobin. | Hematol Oncol Clin North Am | 2014 | https://conductscience.org/library/papers/24589263 | PubMed |
| 4 | 27378309 | GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease. | Br J Haematol | 2016 | https://conductscience.org/library/papers/27378309 | PubMed |
| 5 | 29127281 | Structural and Functional Insight of Sphingosine 1-Phosphate-Mediated Pathogenic Metabolic Reprogramming in Sickle Cell Disease. | Sci Rep | 2017 | https://conductscience.org/library/papers/29127281 | PubMed |
| 6 | 327846 | Red cell 2,3-diphosphoglycerate and oxygen affinity. | Anaesthesia | 1977 | https://conductscience.org/library/papers/327846 | PubMed |
| 7 | 6853710 | Pyridoxal phosphate as an antisickling agent in vitro. | J Clin Invest | 1983 | https://conductscience.org/library/papers/6853710 | PubMed |
| 8 | 32527859 | Allosteric control of hemoglobin S fiber formation by oxygen and its relation to the pathophysiology of sickle cell disease. | Proc Natl Acad Sci U S A | 2020 | https://conductscience.org/library/papers/32527859 | PubMed |
| 9 | 5549196 | The effect of 2,3-DPG on the sickling phenomenon. | Blood | 1971 | https://conductscience.org/library/papers/5549196 | PubMed |
| 10 | 23297128 | Sickle hemoglobin disturbs normal coupling among erythrocyte O2 content, glycolysis, and antioxidant capacity. | Blood | 2013 | https://conductscience.org/library/papers/23297128 | PubMed |
| 11 | 28760888 | AG-348 enhances pyruvate kinase activity in red blood cells from patients with pyruvate kinase deficiency. | Blood | 2017 | https://conductscience.org/library/papers/28760888 | PubMed |
| 12 | 5443181 | Effect of 2,3-diphosphoglycerate on oxygen affinity of blood in sickle cell anemia. | J Clin Invest | 1970 | https://conductscience.org/library/papers/5443181 | PubMed |
| 13 | 31763707 | Hemoglobin S polymerization and sickle cell disease: A retrospective on the occasion of the 70th anniversary of Pauling's Science paper. | Am J Hematol | 2020 | https://conductscience.org/library/papers/31763707 | PubMed |
| 14 | 31483964 | Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency. | N Engl J Med | 2019 | https://conductscience.org/library/papers/31483964 | PubMed |
| 15 | 21170046 | Detrimental effects of adenosine signaling in sickle cell disease. | Nat Med | 2011 | https://conductscience.org/library/papers/21170046 | PubMed |
| 16 | 2393711 | 2,3-Diphosphoglycerate and intracellular pH as interdependent determinants of the physiologic solubility of deoxyhemoglobin S. | Blood | 1990 | https://conductscience.org/library/papers/2393711 | PubMed |
| 17 | 31762454 | Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry. | J Vis Exp | 2019 | https://conductscience.org/library/papers/31762454 | PubMed |
| 18 | 3753004 | The effect of 2,3-diphosphoglycerate on the solubility of deoxyhemoglobin S. | Arch Biochem Biophys | 1986 | https://conductscience.org/library/papers/3753004 | PubMed |
| 19 | 7057919 | Release of spectrin-free spicules on reoxygenation of sickled erythrocytes. | Nature | 1982 | https://conductscience.org/library/papers/7057919 | PubMed |
| 20 | 29549173 | Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study. | Blood | 2018 | https://conductscience.org/library/papers/29549173 | PubMed |
Cited by16
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 27 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41973551 | The pyruvate kinase activator etavopivat (FT-4202) limits pulmonary and systemic sequelae of sepsis in a mouse LPS model. | Am J Physiol Lung Cell Mol Physiol | 2026 | https://conductscience.org/library/papers/41973551 | PubMed |
| 41111336 | Evaluating anti-sickling therapies for sickle cell disease: a microfluidic assay for red blood cell-mediated microvascular occlusion under hypoxia. | Lab Chip | 2025 | https://conductscience.org/library/papers/41111336 | PubMed |
| 40324066 | A novel mouse model of hemoglobin SC disease reveals mechanisms underlying beneficial effects of hydroxyurea. | Blood | 2025 | https://conductscience.org/library/papers/40324066 | PubMed |
| 39828781 | A review on disease modifying pharmacologic therapies for sickle cell disease. | Ann Hematol | 2025 | https://conductscience.org/library/papers/39828781 | PubMed |
| 38915775 | Modulation of the allosteric and vasoregulatory arms of erythrocytic oxygen transport. | Front Physiol | 2024 | https://conductscience.org/library/papers/38915775 | PubMed |
| 38876253 | Endogenous small molecule effectors in GATA transcription factor mechanisms governing biological and pathological processes. | Exp Hematol | 2024 | https://conductscience.org/library/papers/38876253 | PubMed |
| 38118071 | Recent developments in the use of pyruvate kinase activators as a new approach for treating sickle cell disease. | Blood | 2024 | https://conductscience.org/library/papers/38118071 | PubMed |
| 38066891 | Pyruvate kinase activators: targeting red cell metabolism in sickle cell disease. | Hematology Am Soc Hematol Educ Program | 2023 | https://conductscience.org/library/papers/38066891 | PubMed |
| 37934880 | One-year safety and efficacy of mitapivat in sickle cell disease: follow-up results of a phase 2, open-label study. | Blood Adv | 2023 | https://conductscience.org/library/papers/37934880 | PubMed |
| 37451304 | Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission. | Lancet Haematol | 2023 | https://conductscience.org/library/papers/37451304 | PubMed |
| 36971592 | In vivo evaluation of the effect of sickle cell hemoglobin S, C and therapeutic transfusion on erythrocyte metabolism and cardiorenal dysfunction. | Am J Hematol | 2023 | https://conductscience.org/library/papers/36971592 | PubMed |
| 35793591 | Limitations of mouse models for sickle cell disease conferred by their human globin transgene configurations. | Dis Model Mech | 2022 | https://conductscience.org/library/papers/35793591 | PubMed |
| 35587865 | Revisiting anemia in sickle cell disease and finding the balance with therapeutic approaches. | Blood | 2022 | https://conductscience.org/library/papers/35587865 | PubMed |
| 35366607 | Mitapivat increases ATP and decreases oxidative stress and erythrocyte mitochondria retention in a SCD mouse model. | Blood Cells Mol Dis | 2022 | https://conductscience.org/library/papers/35366607 | PubMed |
| 35019238 | Safety, Pharmacokinetics, and Pharmacodynamics of Etavopivat (FT-4202), an Allosteric Activator of Pyruvate Kinase-R, in Healthy Adults: A Randomized, Placebo-Controlled, Double-Blind, First-in-Human Phase 1 Trial. | Clin Pharmacol Drug Dev | 2022 | https://conductscience.org/library/papers/35019238 | PubMed |
| 34803737 | Generation and Export of Red Blood Cell ATP in Health and Disease. | Front Physiol | 2021 | https://conductscience.org/library/papers/34803737 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33944896
GET https://conductscience.org/api/papers/v1/33944896/references?page=2